Remdesivir | TERIS agent - 6800

TERIS Summary
TERIS Agent Number: 6800 Bibliographic Search Date:  05/2022
Agent Name: REMDESIVIR    


Remdesivir is a nucleotide analog with broad-spectrum antiviral activity that is administered intravenously in the treatment of SARS-CoV-2 (which causes COVID-19) and other serious viral infections.

Magnitude of Teratogenic Risk to Child Born After Exposure During Gestation:

Quality and Quantity of Data on Which Risk Estimate is Based:



Summary of Teratology Studies:


No epidemiological studies of congenital anomalies among infants whose mothers were treated with remdesivir during pregnancy have been reported.


Nine women who were hospitalized with COVID-19 and received remdesivir during the second or third trimester of pregnancy delivered healthy infants in separate case reports (McCoy et al., 2020; Saroyo et al., 2021).

No stillbirths or neonatal deaths were reported among 33 infants born to 64 women with severe or critical COVID-19 disease during the second or third trimester of pregnancy in one series (Pierce-Williams et al., 2020). Seventeen of the 64 women were treated with remdesivir.

In separate case reports, two preterm infants (25 weeks and 29 weeks) were born to mothers with severe COVID-19 pneumonia who received several medications, including remdesivir, prior to delivery (Easterlin et al., 2020; Jacobson et al., 2021). Preterm delivery was attributed to maternal illness in both cases. A healthy full-term infant was born to a mother with severe COVID-19 pneumonia who received remdesivir in the third trimester (Dande et al., 2021).

Six pregnant women were given remdesivir in a randomized, controlled trial of four different medications designed to treat Ebola virus disease (Mulangu et al., 2019). No serious adverse neonatal events attributable to remdesivir were reported in this study.


Animal teratology studies of remdesivir conducted by the manufacturer have not been published in the peer-reviewed literature.

Selected References:
(Each paper is classified as a review [R], human case report [C], human epidemiological study [E], human clinical series [S], animal study [A], or other [O].)

Dande R, Qureshi A, Persaud K, Puri C, Zulfiqar S, Awasthi S: Remdesivir in a pregnant patient with COVID-19 pneumonia. J Community Hosp Intern Med Perspect 11(1):103-106, 2021. [C]

Easterlin MC, De Beritto T, Yeh AM, Wertheimer FB, Ramanathan R: Extremely preterm infant born to a mother with severe COVID-19 pneumonia. J Investig Med High Impact Case Rep 8:1-5, 2020. [C]

Jacobson J, Antony K, Beninati M, Alward W, Hoppe KK: Use of dexamethasone, remdesivir, convalescent plasma and prone positioning in the treatment of severe COVID-19 infection in pregnancy: a case report. Case Rep Womens Health 29:e00273, 2021. [C]

McCoy JA, Short WR, Srinivas SK, Levine LD, Hirshberg A. Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center. Am J Obstet Gynecol MFM 2(3):100164. 2020. [S]

Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali R, Coulibaly S, Levine AC, Grais R, Diaz J, Lane HC, Muyembe-Tamfum J-J; PALM Writing Group: A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med 381(24):2293-2303, 2019. [E]

Pierce-Williams RAM, Burd J, Felder L, Khoury R, Bernstein PS, Avila K, Penfield CA, Roman AS, DeBolt CA, Stone JL, Bianco A, Kern-Goldberger AR, Hirshberg A, Srinivas SK, Jayakumaran JS, Brandt JS, Anastasio H, Birsner M, O'Brien DS, Sedev HM, Dolin CD, Schnettler WT, Suhag A, Ahluwalia S, Navathe RS, Khalifeh A, Anderson K, Berghella V: Clinical course of severe and critical COVID-19 in hospitalized pregnancies: a United States cohort study. Am J Obstet Gynecol MFM 2(3):100134, 2020. [S]

Saroyo YB, Rumondang A, Febriana IS, Harzif AK, Irwinda R: Remdesivir treatment for COVID 19 in pregnant patients with moderate to severe symptoms: serial case report. Infect Dis Rep 13(2):437-443, 2021. [C]



Pregnancy studies have been established for women infected with, or exposed to, the SARS-CoV-2 coronavirus (which causes COVID-19) during pregnancy.

Healthcare providers are encouraged to enroll such patients, whether or not they have been treated with remdesivir, in the MotherToBaby Pregnancy Study by calling 877-311-8972 or in the PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY) Study by calling 415-754-3729.